Compare Standard Lithium Ltd (SLI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Standard Lithium Ltd vs TransMedics Group Inc — how do they compare? Standard Lithium Ltd trades at $1.58 (market cap $398.07M), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 6.9× Standard Lithium Ltd's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Standard Lithium Ltd for 23 Days and TransMedics Group Inc for 24 Days on average.
| SLI | TMDX | |
|---|---|---|
Market Cap | $398.07M | $2.74B |
Volume | 1,564,155 | 949,331 |
Sector | Basic Materials | Health |
52-Week High | $5.65 | $150.42 |
52-Week Low | $1.58 | $61.99 |
Typical Hold Time | 23 Days | 24 Days |
Enterprise Value | $260.98M | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Standard Lithium (SLI) trades at $1.61, down 2.42% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company is pre-revenue with significant losses, reporting negative EBITDA of $50.53 million for 2025, but has made progress on its South West Arkansas lithium project, targeting a final investment decision by end of 2026. Analyst consensus is unanimously bullish with a $3.83 price target.
The investment case hinges on successful project execution and commercialization, offering substantial upside if milestones are met. Key risks include the capital-intensive nature of lithium production, execution delays, and reliance on future financing, with current cash flow sustained by financing activities.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
